Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU AI Act Amendments Get Green Light From Parliament Committees In Latest Vote

Executive Summary

The European Commission’s hotly debated AI Act proposal is a step closer to becoming law after 13 amendments were voted in by members of the European Parliament. The landmark legislation is set to have an enormous impact on all AI products, including many medical devices.

You may also be interested in...



EU AI Act Proposal Adopted By Parliament In Landslide Plenary Vote

The European Commission’s proposed Artificial Intelligence Act is now set to enter high-level negotiations after MEPs voted overwhelmingly in favor of the draft text in a plenary vote.

EU AI Act Legal Deep-Dive Part 1: What Can Medtech Expect, And When?

The text of the European Commission’s proposed AI Act is expected to enter the EU high-level negotiation stage within weeks, yet many questions remain as to what the final regulation will entail. Lawyers from Cooley LLP tell Medtech Insight why considerable changes to the text are possible, and what the new law is likely to mean for medtech.

ChatGPT Unleashed: Generative AI Use Cases Taking Off In Pharma

As generative AI and its star avatar, ChatGPT, take the world by storm, pharma is seeing traction for use cases around smarter pharmacovigilance and commercial marketing content development, among others. Senior executives from Indegene discuss this and more in an interview with Scrip.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel